Product | Indication | Dosage form | Strength |
---|---|---|---|
Promethazine | Agitation and restlessness | Oral solution | 20mg/ ml 100mg/ ml |
Quetiapine * | Psychosis, schizophrenia, bipolar disoder | Film-coated tablets | 25, 50, 100, 150, 200, 300 and 400 mg |
Rasagiline (tartrate) | Parkinson's | Tablets | 1 mg |
Risperidone | Psychosis, schizophrenia, bipolar disoder | Film-coated tablets | 1, 3 and 6 mg |
Sodium Oxybate | Narcolepsy | Oral solution | 500 mg/ml |
Sulpiride | Psychosis, schizophrenia | Tablets | 50 and 200 mg |
Sultiame * | Epilepsy, convulsions | Film-coated tablets | 50, 100 and 200 mg |
Tolcapone | Parkinson's | Film-coated tablets | 100 mg |
Tranylcypromine | Depression | Film-coated tablets | 10, 20 and 40 mg |
Tranylcypromine | Depression | Film-coated tablets | 10, 20 and 40 mg |
Trazodone | Depression | XR tablets | 75 and 150 mg |
Trimipramine | Depression | Oral drops, solution | 40mg / ml |
Valproate | Epilepsy | Oral solution | 300mg/ ml (100ml) 300mg/ 5ml (250ml) |
Zonisamide | Epilepsy | Hard capsules | 25, 50 and 100 mg |
Zonisamide | Epilepsy | IR tablets | 25, 50, 100, 200 and 300 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.